RAPPORT THERAPEUTICS INC

Company Overview

Rapport Therapeutics (RAPP) is a clinical-stage biotechnology company developing precision small-molecule neuromedicines using a proprietary receptor-associated protein (RAP) platform. Its lead program, RAP‑219, is a TARP α8‑selective AMPA receptor negative allosteric modulator targeted at refractory focal epilepsy (Phase 2a ongoing with topline expected Q3/Sept 2025) and planned bipolar mania and DPNP programs (the latter currently on FDA clinical hold). The company has no product revenue, outsources manufacturing to CMOs, relies on an exclusive Janssen license and collaborations (e.g., NeuroPace), and drives value primarily through clinical and regulatory milestones; cash was ~$305M at 12/31/24 and ~$260M at 6/30/25, which management says funds operations into 2026.

Executive Compensation Practices

Compensation at Rapport is likely equity‑heavy and milestone‑oriented, consistent with small clinical‑stage biotechs: the filings show materially higher stock‑based compensation tied to headcount expansion and public‑company costs and identify stock awards and option valuation as critical accounting items. With large R&D spend (R&D was $60.9M in 2024, up $32.9M year‑over‑year) and no product revenue, executives’ incentives will be driven by clinical readouts (PET occupancy, Phase 2a topline), enrollment/timing metrics, CMO/CRO deliverables, and successful resolution of regulatory holds. Expect typical biotech features such as time‑vested options/RSUs, potential milestone or performance awards connected to regulatory or partnering events, and change‑in‑control/retention protections to retain scientific leadership (the company explicitly increased personnel with many Ph.D./M.D. staff).

Insider Trading Considerations

Insider trading at Rapport will be highly event‑driven: meaningful clustering is likely around PET confirmations, Phase 2a topline (Sept 2025), IND communications (including the DPNP hold resolution), and partnering/license milestones from Janssen or NeuroPace. Post‑IPO dynamics matter — the company disclosed significant financing activity and increased liquid balances; insiders may use post‑IPO windows to diversify (common after lock‑ups expire), while purchases by insiders around or after positive clinical data would be especially informative. Regulatory constraints to watch include Section 16 reporting, routine blackout periods ahead of material disclosures, and the practical impact of an FDA clinical hold (which can trigger internal trading bans); use of Rule 10b5‑1 plans is common in this sector to avoid allegations of trading on material nonpublic information.